Vijay Pande: small bets after $4B a16z biotech

Vijay Pande left a16z's roughly $4 billion biotech practice to start AI-native VZVC, favoring fewer, smaller bets. Pande says biology is shifting from discovery to engineering, clinical trials remain costly, and open shared datasets, not walled ones, will let AI transform medicine.